請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67726完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 符文美(Wen-Mei Fu) | |
| dc.contributor.author | Wen Lee | en |
| dc.contributor.author | 李雯 | zh_TW |
| dc.date.accessioned | 2021-06-17T01:46:20Z | - |
| dc.date.available | 2017-09-12 | |
| dc.date.copyright | 2017-09-12 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-07-26 | |
| dc.identifier.citation | Attal, N., G. Cruccu, R. Baron, M. Haanpaa, P. Hansson, T. S. Jensen, T. Nurmikko and S. European Federation of Neurological (2010). 'EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.' Eur J Neurol 17(9): 1113-e1188.
Attal, N., G. Cruccu, M. Haanpaa, P. Hansson, T. S. Jensen, T. Nurmikko, C. Sampaio, S. Sindrup, P. Wiffen and E. T. Force (2006). 'EFNS guidelines on pharmacological treatment of neuropathic pain.' Eur J Neurol 13(11): 1153-1169. Austin, P. J. and G. Moalem-Taylor (2010). 'The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines.' J Neuroimmunol 229(1-2): 26-50. Bennett, M. (2001). 'The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs.' Pain 92(1-2): 147-157. Borsook, D. (2012). 'Neurological diseases and pain.' Brain 135(Pt 2): 320-344. Bouhassira, D., N. Attal, H. Alchaar, F. Boureau, B. Brochet, J. Bruxelle, G. Cunin, J. Fermanian, P. Ginies, A. Grun-Overdyking, H. Jafari-Schluep, M. Lanteri-Minet, B. Laurent, G. Mick, A. Serrie, D. Valade and E. Vicaut (2005). 'Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).' Pain 114(1-2): 29-36. Brandolini, L., E. Benedetti, P. A. Ruffini, R. Russo, L. Cristiano, A. Antonosante, M. d'Angelo, V. Castelli, A. Giordano, M. Allegretti and A. Cimini (2017). 'CXCR1/2 pathways in paclitaxel-induced neuropathic pain.' Oncotarget 8(14): 23188-23201. Cao, D. L., Z. J. Zhang, R. G. Xie, B. C. Jiang, R. R. Ji and Y. J. Gao (2014). 'Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2.' Exp Neurol 261: 328-336. Carreira, E. U., V. Carregaro, M. M. Teixeira, A. Moriconi, A. Aramini, W. A. Verri, Jr., S. H. Ferreira, F. Q. Cunha and T. M. Cunha (2013). 'Neutrophils recruited by CXCR1/2 signalling mediate post-incisional pain.' Eur J Pain 17(5): 654-663. Chen, G., C. K. Park, R. G. Xie, T. Berta, M. Nedergaard and R. R. Ji (2014). 'Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice.' Brain 137(Pt 8): 2193-2209. Chung, S. H. K. a. J. M. (1992). 'An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.' Colloca, L., T. Ludman, D. Bouhassira, R. Baron, A. H. Dickenson, D. Yarnitsky, R. Freeman, A. Truini, N. Attal, N. B. Finnerup, C. Eccleston, E. Kalso, D. L. Bennett, R. H. Dworkin and S. N. Raja (2017). 'Neuropathic pain.' Nat Rev Dis Primers 3: 17002. Costigan, M., J. Scholz and C. J. Woolf (2009). 'Neuropathic pain: a maladaptive response of the nervous system to damage.' Annu Rev Neurosci 32: 1-32. Dworkin, R. H., M. Backonja, M. C. Rowbotham, R. R. Allen, C. R. Argoff, G. J. Bennett, M. C. Bushnell, J. T. Farrar, B. S. Galer, J. A. Haythornthwaite, D. J. Hewitt, J. D. Loeser, M. B. Max, M. Saltarelli, K. E. Schmader, C. Stein, D. Thompson, D. C. Turk, M. S. Wallace, L. R. Watkins and S. M. Weinstein (2003). 'Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.' Arch Neurol 60(11): 1524-1534. Dworkin, R. H., A. B. O'Connor, M. Backonja, J. T. Farrar, N. B. Finnerup, T. S. Jensen, E. A. Kalso, J. D. Loeser, C. Miaskowski, T. J. Nurmikko, R. K. Portenoy, A. S. Rice, B. R. Stacey, R. D. Treede, D. C. Turk and M. S. Wallace (2007). 'Pharmacologic management of neuropathic pain: evidence-based recommendations.' Pain 132(3): 237-251. Ellis, A. and D. L. Bennett (2013). 'Neuroinflammation and the generation of neuropathic pain.' Br J Anaesth 111(1): 26-37. Finnerup, N. B. and N. Attal (2016). 'Pharmacotherapy of neuropathic pain: time to rewrite the rulebook?' Pain Manag 6(1): 1-3. Finnerup, N. B., N. Attal, S. Haroutounian, E. McNicol, R. Baron, R. H. Dworkin, I. Gilron, M. Haanpaa, P. Hansson, T. S. Jensen, P. R. Kamerman, K. Lund, A. Moore, S. N. Raja, A. S. Rice, M. Rowbotham, E. Sena, P. Siddall, B. H. Smith and M. Wallace (2015). 'Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.' Lancet Neurol 14(2): 162-173. Finnerup, N. B., S. Haroutounian, P. Kamerman, R. Baron, D. L. Bennett, D. Bouhassira, G. Cruccu, R. Freeman, P. Hansson, T. Nurmikko, S. N. Raja, A. S. Rice, J. Serra, B. H. Smith, R. D. Treede and T. S. Jensen (2016). 'Neuropathic pain: an updated grading system for research and clinical practice.' Pain 157(8): 1599-1606. Galloway, C. and M. Chattopadhyay (2013). 'Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in Type 2 diabetes.' Cytokine 63(1): 1-5. Gao, Y. J. and R. R. Ji (2010). 'Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.' Pharmacol Ther 126(1): 56-68. Gao, Y. J., L. Zhang, O. A. Samad, M. R. Suter, K. Yasuhiko, Z. Z. Xu, J. Y. Park, A. L. Lind, Q. Ma and R. R. Ji (2009). 'JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain.' J Neurosci 29(13): 4096-4108. Ghasemzadeh, M., Z. S. Kaplan, I. Alwis, S. M. Schoenwaelder, K. J. Ashworth, E. Westein, E. Hosseini, H. H. Salem, R. Slattery, S. R. McColl, M. J. Hickey, Z. M. Ruggeri, Y. Yuan and S. P. Jackson (2013). 'The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi.' Blood 121(22): 4555-4566. Grimm, M. C., A. Ben-Baruch, D. D. Taub, O. M. Howard, J. H. Resau, J. M. Wang, H. Ali, R. Richardson, R. Snyderman and J. J. Oppenheim (1998). 'Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization.' J Exp Med 188(2): 317-325. Hingtgen, C. M. (2006). 'A new 'kine' of pain: MCP-1 and sensory neuron excitability. Focus on 'MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia'.' J Neurophysiol 96(5): 2171-2172. Ji, R. R., T. Berta and M. Nedergaard (2013). 'Glia and pain: is chronic pain a gliopathy?' Pain 154 Suppl 1: S10-28. Ji, R. R., Z. Z. Xu and Y. J. Gao (2014). 'Emerging targets in neuroinflammation-driven chronic pain.' Nat Rev Drug Discov 13(7): 533-548. Jiang, B. C., D. L. Cao, X. Zhang, Z. J. Zhang, L. N. He, C. H. Li, W. W. Zhang, X. B. Wu, T. Berta, R. R. Ji and Y. J. Gao (2016). 'CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5.' J Clin Invest 126(2): 745-761. Johnston, I. N., E. D. Milligan, J. Wieseler-Frank, M. G. Frank, V. Zapata, J. Campisi, S. Langer, D. Martin, P. Green, M. Fleshner, L. Leinwand, S. F. Maier and L. R. Watkins (2004). 'A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine.' J Neurosci 24(33): 7353-7365. Jung, H., P. T. Toth, F. A. White and R. J. Miller (2008). 'Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons.' J Neurochem 104(1): 254-263. Kawasaki, Y., L. Zhang, J. K. Cheng and R. R. Ji (2008). 'Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord.' J Neurosci 28(20): 5189-5194. Kiguchi, N., Y. Kobayashi, T. Maeda, Y. Fukazawa, K. Tohya, M. Kimura and S. Kishioka (2012). 'Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain.' J Pharmacol Exp Ther 340(3): 577-587. Li, H., W. Xie, J. A. Strong and J. M. Zhang (2007). 'Systemic antiinflammatory corticosteroid reduces mechanical pain behavior, sympathetic sprouting, and elevation of proinflammatory cytokines in a rat model of neuropathic pain.' Anesthesiology 107(3): 469-477. Li, Y., M. J. Dorsi, R. A. Meyer and A. J. Belzberg (2000). 'Mechanical hyperalgesia after an L5 spinal nerve lesion in the rat is not dependent on input from injured nerve fibers.' Pain 85(3): 493-502. Livak, K. J. and T. D. Schmittgen (2001). 'Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.' Methods 25(4): 402-408. Lopes, A. H., L. Brandolini, A. Aramini, G. Bianchini, R. L. Silva, A. C. Zaperlon, W. A. Verri, Jr., J. C. Alves-Filho, F. Q. Cunha, M. M. Teixeira, M. Allegretti and T. M. Cunha (2016). 'DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain.' Pharmacol Res 103: 69-79. Ma, C., Y. Shu, Z. Zheng, Y. Chen, H. Yao, K. W. Greenquist, F. A. White and R. H. LaMotte (2003). 'Similar electrophysiological changes in axotomized and neighboring intact dorsal root ganglion neurons.' J Neurophysiol 89(3): 1588-1602. McCarberg, B. H. and R. Billington (2006). 'Consequences of neuropathic pain: quality-of-life issues and associated costs.' Am J Manag Care 12(9 Suppl): S263-268. McMahon, S. B. and M. Malcangio (2009). 'Current challenges in glia-pain biology.' Neuron 64(1): 46-54. Milligan, E. D., E. M. Sloane and L. R. Watkins (2008). 'Glia in pathological pain: a role for fractalkine.' J Neuroimmunol 198(1-2): 113-120. Qin, X., Y. Wan and X. Wang (2005). 'CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons.' J Neurosci Res 82(1): 51-62. Raghuwanshi, S. K., Y. Su, V. Singh, K. Haynes, A. Richmond and R. M. Richardson (2012). 'The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions.' J Immunol 189(6): 2824-2832. Saab, C. Y., S. G. Waxman and B. C. Hains (2008). 'Alarm or curse? The pain of neuroinflammation.' Brain Res Rev 58(1): 226-235. Scholz, J. and C. J. Woolf (2007). 'The neuropathic pain triad: neurons, immune cells and glia.' Nat Neurosci 10(11): 1361-1368. Shaw, S. K., S. A. Owolabi, J. Bagley, N. Morin, E. Cheng, B. W. LeBlanc, M. Kim, P. Harty, S. G. Waxman and C. Y. Saab (2008). 'Activated polymorphonuclear cells promote injury and excitability of dorsal root ganglia neurons.' Exp Neurol 210(2): 286-294. Souza, G. R., J. Talbot, C. M. Lotufo, F. Q. Cunha, T. M. Cunha and S. H. Ferreira (2013). 'Fractalkine mediates inflammatory pain through activation of satellite glial cells.' Proc Natl Acad Sci U S A 110(27): 11193-11198. Suter, M. R., Y. R. Wen, I. Decosterd and R. R. Ji (2007). 'Do glial cells control pain?' Neuron Glia Biol 3(3): 255-268. Szabo, I., X. H. Chen, L. Xin, M. W. Adler, O. M. Howard, J. J. Oppenheim and T. J. Rogers (2002). 'Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain.' Proc Natl Acad Sci U S A 99(16): 10276-10281. Tesfaye, S., A. J. Boulton and A. H. Dickenson (2013). 'Mechanisms and management of diabetic painful distal symmetrical polyneuropathy.' Diabetes Care 36(9): 2456-2465. Thacker, M. A., A. K. Clark, T. Bishop, J. Grist, P. K. Yip, L. D. Moon, S. W. Thompson, F. Marchand and S. B. McMahon (2009). 'CCL2 is a key mediator of microglia activation in neuropathic pain states.' Eur J Pain 13(3): 263-272. Treede, R. D., T. S. Jensen, J. N. Campbell, G. Cruccu, J. O. Dostrovsky, J. W. Griffin, P. Hansson, R. Hughes, T. Nurmikko and J. Serra (2008). 'Neuropathic pain: redefinition and a grading system for clinical and research purposes.' Neurology 70(18): 1630-1635. Verri, W. A., Jr., T. M. Cunha, C. A. Parada, S. Poole, F. Q. Cunha and S. H. Ferreira (2006). 'Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?' Pharmacol Ther 112(1): 116-138. Watson, J. C. and P. Sandroni (2016). 'Central Neuropathic Pain Syndromes.' Mayo Clin Proc 91(3): 372-385. White, F. A., H. Jung and R. J. Miller (2007). 'Chemokines and the pathophysiology of neuropathic pain.' Proc Natl Acad Sci U S A 104(51): 20151-20158. Woolf, C. J. and R. J. Mannion (1999). 'Neuropathic pain: aetiology, symptoms, mechanisms, and management.' Lancet 353(9168): 1959-1964. Xu, J., M. D. Zhu, X. Zhang, H. Tian, J. H. Zhang, X. B. Wu and Y. J. Gao (2014). 'NFkappaB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice.' J Neuroinflammation 11: 38. Zhang, J. M. and J. An (2007). 'Cytokines, inflammation, and pain.' Int Anesthesiol Clin 45(2): 27-37. Zhang, Z. J., D. L. Cao, X. Zhang, R. R. Ji and Y. J. Gao (2013). 'Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons.' Pain 154(10): 2185-2197. Zhang, Z. J., B. C. Jiang and Y. J. Gao (2017). 'Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain.' Cell Mol Life Sci. Zhou, Y., R. J. Li, M. Li, X. Liu, H. Y. Zhu, Z. Ju, X. Miao and G. Y. Xu (2016). 'Overexpression of GRK6 attenuates neuropathic pain via suppression of CXCR2 in rat dorsal root ganglion.' Mol Pain 12. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67726 | - |
| dc.description.abstract | 神經病變性疼痛一直以來因為疾病本身非常複雜，在治療不易、預後不好的情況下，逐漸成為需要被重視的問題。在定義上，神經病變性疼痛是因為在周邊和中樞神經系統內的體感覺系統受到損傷或疾病的影響而產生的，一般可分類為中樞或周邊神經病變性疼痛。直到目前為止，既有的藥物治療效果都不甚明顯，因此，許多人仍致力於釐清神經病變性疼痛的致病機制，並期望於其中找出可作為藥物開發的標的對象。許多報導指出神經發炎參與神經病變性疼痛的病理過程，而且細胞激素/趨化激素的作用路徑也在神經發炎中扮演重要的角色，未來可能發展作為治療的標的，但是詳細的機制尚未釐清。本篇研究的主要目的即是藉由觀察動物疾病模式的腦脊髓液，尋找參與神經病變性疼痛病理過程相對重要的細胞激素/趨化激素。我們選用綁住單側L5 脊神經並剪斷的手術方式形成疾病模式，接著利用電子式疼痛測量儀和老鼠腳底熱刺激儀來做疼痛行為(對溫度和機械性刺激產生痛覺過敏)的評估。我們利用細胞激素/趨化激素微陣列觀察腦脊髓液，發現其中趨化激素CXCL7 在疾病模式比起控制組有顯著的表現量增強，另外，我們也觀察到在疾病模式單側的脊椎背角樣本中CXCL7 的蛋白質和mRNA 的表現量比起控制組都有增加的趨勢。接著，利用脊髓腔注射的方式直接給予CXCL7發現會引發老鼠產生痛覺敏感，也在組織切片中看到活化的神經膠細胞和神經胜肽CGRP 表現量增加。因為CXCL7 是藉由結合CXCR1 和CXCR2 產生下游的反應，所以進一步使用CXCR1/CXCR2的拮抗劑reparixin-L-lysine salt，當reparixin 和CXCL7 用脊髓腔注射的方式同時給予，可以觀察到reparixin 拮抗CXCL7 引發的痛覺過敏。因此，在疾病模式中給予reparixin 可以減少手術產生的痛覺敏感，在組織切片也看到活化的神經膠細胞比控制組少。最後，依據觀察到的現象和實驗結果，我們推測CXCL7 可能參與神經病變性疼痛的病理過程，而且CXCR1/CXCR2 的拮抗劑或許可以發展為治療神經病變性疼痛的藥物。 | zh_TW |
| dc.description.abstract | Neuropathic pain is a problem in general population because of the complexity of neuropathic symptoms, poor outcomes and difficult treatment decision. Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system and can be subtyped as central and peripheral neuropathic pain. Until now, conventional pharmacological treatments for neuropathic pain are effective in <50% of patients. Therefore, clarifying actual mechanism in neuropathic pain and finding a new target remain important parts for developing new drugs. Neuroinflammation has been reported to be involved in the pathophysiology of neuropathic pain and is an emerging target of treatment. Although the cytokine/chemokine pathways play a major role in neuroinflammation, the exact mechanism in neuropathic pain remains unclear. To investigate the cytokines/chemokines changes, we used neuropathic pain animal model produced by unilateral L5 spinal nerve ligation-and-cut (SNL) and electronic von Frey test and plantar test for pain assessment (including
mechanical and thermal hyperalgesia, respectively). We then screened cytokine expression in the cerebrospinal fluid using cytokine array, and it was found that CXCL7 increased markedly in SNL rats compared with control. The expression levels of both protein and messenger RNA of CXCL7 were up-regulated in spinal cord dorsal horn samples of SNL rats compared with control.Furthermore, intrathecal administration of recombinant chemokine CXCL7 induced mechanical and thermal hyperalgesia and increased glia activation and sensory neuropeptide CGRP expression level. To investigate the involvement of CXCR1/CXCR2, receptors of CXCL7, a CXCR1/CXCR2 antagonist reparixin-L-lysine salt (reparixin) was co-administered intrathecally with CXCL7 via osmotic pump. It was found that CXCR1/CXCR2 antagonist reversed CXCL7-induced hyperalgesia. We also evaluated the effect of CXCR1/CXCR2 in SNL rats. Right after SNL, intrathecal infusion of CXCR1/CXCR2 antagonist reparixin via osmotic pump for 7 days attenuated SNL-induced hyperalgesia and glia activation. These results indicate that CXCL7 might be involved in neuropathic pain and CXCR1/CXCR2 antagonist might be developed as drug for the treatment of neuropathic pain. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T01:46:20Z (GMT). No. of bitstreams: 1 ntu-106-R04443014-1.pdf: 3845106 bytes, checksum: 56ec9eaad60752db45870870a8e85f04 (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | Figure contents…………………………...………………………………………...…………………...i
Table Contents …………………………………………………………...……....………………….iii Abbreviations..…………………………………………………………...…………....……………….iv 中文摘要………………………………………………………………………............…………………...v Abstract………………………………………………………………………...……………......……... vi Chapter 1 Introduction 1-1. Neuropathic pain……………………………………………………......…………………… 1 1-2. Neuro-immune interaction……………..………………….………………………………5 1-3. Chemokines in neuropathic pain ……………………………………………………7 1-4. Aim………………………………………………………………………………….............……..9 Chapter 2 Materials and Methods 2-1. Regents…..…………….…..…………………………………………….......……………… 17 2-2. Animals………………..……………….…..……………………………..……...……..…. 17 2-3. Neuropathic pain animal model…………………………..…………………… 17 2-4. Intrathecal catheterization…..……………………..…………………...19 2-5. Drug administration….……..…………………………………...………………...20 2-6. Behavior tests....................................20 2-6-1. Electronic von Frey test..………………….…………………..……… .20 2-6-2. Plantar test……………….………………………………………………......……...21 2-7. Cytokine array……………..……………………………………….....…………………… 22 2-8. Enzyme-linked immunosorbent assay….…………….…………………….23 2-9. Quantitative polymerase chain reaction…………………….………24 2-10. Immunohistochemistry staining……………………………………….……..25 2-11. Statistical analysis………...……………………………………..……………….26 Chapter 3 Results 3-1. Cytokines/Chemokines expression profile in cerebrospinal fluid of rats after unilateral L5 spinal nerve ligation-and-cut (SNL)…………………………………………………..………...27 3-2. Intrathecal administration of CXCL7 induces mechanical and thermal hyperalgesia…………………...….……………...28 3-3. Intrathecal administration of CXCL7 increases spinal glia cells activation and CGRP expression………………………………..29 3-4. Intrathecal administration of CXCR1/CXCR2 antagonist reparixin antagonizes CXCL7-induced hyperalgesia…......30 3-5. Intrathecal administration of CXCR1/CXCR2 antagonist reparixin attenuates SNL-induced hyperalgesia……...……...31 3-6. Intrathecal administration of CXCR1/CXCR2 antagonist reduces SNL-induced spinal glia cells activation…………………32 Chapter 4 Discussion………..…….………………………………………………………………...45 Reference………………………..………………………………………………………………...........49 | |
| dc.language.iso | en | |
| dc.subject | 神經發炎 | zh_TW |
| dc.subject | 神經病變性疼痛 | zh_TW |
| dc.subject | 趨化激素 | zh_TW |
| dc.subject | CXCL7 | zh_TW |
| dc.subject | CXCR1/CXCR2 拮抗劑 | zh_TW |
| dc.subject | CXCL7 | en |
| dc.subject | Neuropathic pain | en |
| dc.subject | Chemokine | en |
| dc.subject | CXCR1/CXCR2 antagonist | en |
| dc.subject | Neuroinflammation | en |
| dc.subject | reparixin-L-lysine salt | en |
| dc.title | 趨化因子CXCL7在周邊神經損傷引起神經病變性疼痛之探討 | zh_TW |
| dc.title | The role of CXCL7 in peripheral nerve injury-induced neuropathic pain | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林婉婉(Wan-Wan Lin),孫維仁(Wei-Zen Sun),林滿玉(Maan-Yuh Lin) | |
| dc.subject.keyword | 神經病變性疼痛,神經發炎,趨化激素,CXCL7,CXCR1/CXCR2 拮抗劑, | zh_TW |
| dc.subject.keyword | Neuropathic pain,Neuroinflammation,Chemokine,CXCL7,CXCR1/CXCR2 antagonist,reparixin-L-lysine salt, | en |
| dc.relation.page | 60 | |
| dc.identifier.doi | 10.6342/NTU201702002 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-07-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 未授權公開取用 | 3.75 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。